Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > ACADEMIA
ACADEMIA
- SMART Study Retracted from US Journal, Chief Investigator to Resign as Hospital Director
January 22, 2014
- AJMC Announces Guidelines for COI Management at Research and Medical Institutions
December 25, 2013
- Chiba University Finds No Proof of Manipulation in Diovan Study
December 18, 2013
- Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
- Diovan Probe Updates to Come from Nagoya Univ. on Dec. 13, Chiba Univ. on Dec. 17
December 12, 2013
- New Hepatitis C Guidelines Set Triple Therapy Including Simeprevir as 1st Choice
December 11, 2013
- All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato
November 26, 2013
- Edoxaban Demonstrates Non-Inferiority to Warfarin in Stroke Prevention in AF Patients: Daiichi Sankyo
November 22, 2013
- AJMC Approves Draft of COI Management Guidelines
November 20, 2013
- JAMS COI Panel to Nudge JPMA to Create Funding Database
November 19, 2013
- JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
- Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
- Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
- JSH2014 GL for Management of Hypertension to Emphasize Transparency, Remove References to Discredited Papers
October 29, 2013
- Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
- Skills for Clinical Studies Required to Become Authorized Hypertension Specialist: JSH
October 28, 2013
- Kyoto Heart Study Chief Investigator to Leave JSH; JSH Ethics Committee Will Continue Investigation
October 28, 2013
- Japan’s First Guidelines for Hematological Malignancy Treatment Compiled by Japanese Society of Hematology
October 24, 2013
- President of Kyoto Prefectural University of Medicine Reprimanded Over Diovan Scandal, Diovan Study Chief Investigator Returns Retirement Allowance
October 17, 2013
- Shiga University of Medical Science to Unveil Diovan Probe Results at Month-End
October 16, 2013
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…